Thanks for asking and I’m certainly following the epigenetics space. There is just so much going on, it’s hard to keep up. I’ve been doing hours of reading every day.
Moonwalk certainly looks interesting with both Attia and Kaeberlein listed as scientific advisors.
It’s hard to tell how much of the news coming out is hype since as I’ve mentioned there are 28 million CpG sites, some static but many constantly changing, being methylated/deacetylated or demethylated/acetylated sometimes on a daily bases. The static ones, that usually stay the same over the lifespan are the ones they are using to measure epigenetic noise or “epigenetic drift”. This is the basis of Irina Conboy’s Generation Lab Epigenetic clock. But this is just a small subset of the 28 million CpG. At least with these we know what to reset them to, because they are usually unchanging. An example would be the housekeeping genes that need to stay active.
—With partial cell reprogramming it’s less clear where you want to reset them to. You don’t want to regress them past cell differentiation to stem cells - or at least not all of them. Also epigenetics is like a cell memory, I’m not sure you want to erase it all. Seems very complicated and tricky, including the translation from mice to humans.
But in many cases it’s been difficult to determine which switches control what genes, or how to get to them without causing other problems. Using new computing tools and advances in genomic research, a number of biotech companies pushed ahead with research, and are now joined by others seeking to use CRISPR-based tools. Their idea is to use CRISPR components to turn genes on or off, or to alter the expression of several at a time without cutting into or changing DNA.
https://www.biopharmadive.com/news/epigenetic-gene-editing-crispr-epic-tune-chroma/627703/
“I think of the epigenome as a software of the genome,” Aravanis said, likening its ability to control gene expression to the technology used to encode websites and computer programs.
Moonwalk plans to harness that software with computing tools that, Aravanis claims, will help the company examine changes that occur during a biological process called methylation. Moonwalk will use that information to uncover which areas of the epigenome to target, and then go after them with editing technology licensed from Zhang at the Broad.
“People have tried to modify the epigenome, and there have been successes in the past,” he said. “But the broad technology to characterize it completely, modify it at multiple sites and to do it very precisely, that’s new.”
So, you might be able to reboot with a clean copy of Windows, but you’d still need to add back all your data and apps.
Current research has shown that transient expression of Yamanaka factors can rejuvenate cells in mice without fully reprogramming them to an embryonic state or risking de-differentiation into other cell types, suggesting potential for safe application in humans.
Just to show how fluid the epigenetic state is, take a look at this:
Epigenetic age can fluctuate by five years in a single day
https://www.pnas.org/post/journal-club/epigenetic-age-can-fluctuate-five-years-single-day
We often think of aging as a process of progressive methylation of DNA, silencing genes so they don’t function like they did when younger. But here’s a case where demethylating the DNA and activating the genes is what is causing the aging problem.
Cox said: “The human genome is full of bits of viral DNA that crept in there over our evolution, and they’re normally repressed. But as we get older, they jump out again and trigger inflammation, the body’s response to an infection. The problem is the immune system is also old, and so it can’t deal with it.”
https://www.theguardian.com/business/2023/nov/05/british-biotech-races-uss-buff-billionaires-for-secret-of-eternal-youth